Daily Stock Analysis, ARGS, Argos Therapeutics Inc, priceseries

Argos Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
1.55
Close
1.35
High
1.60
Low
1.30
Previous Close
1.48
Daily Price Gain
-0.12
YTD High
5.68
YTD High Date
Jan 9, 2017
YTD Low
1.25
YTD Low Date
Feb 22, 2017
YTD Price Change
-3.60
YTD Gain
-72.73%
52 Week High
13.97
52 Week High Date
Apr 18, 2016
52 Week Low
1.25
52 Week Low Date
Feb 22, 2017
52 Week Price Change
-2.98
52 Week Gain
-68.82%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 20. 2015
5.32
Sep 18. 2015
6.28
20 Trading Days
18.00%
Link
LONG
Oct 5. 2015
5.35
Oct 21. 2015
5.99
12 Trading Days
11.98%
Link
LONG
Jan 19. 2016
2.16
Feb 24. 2016
4.18
25 Trading Days
93.39%
Link
LONG
Feb 29. 2016
4.44
Mar 8. 2016
4.98
6 Trading Days
12.12%
Link
LONG
Mar 24. 2016
5.43
Apr 1. 2016
6.04
5 Trading Days
11.33%
Link
LONG
Apr 4. 2016
6.49
Apr 20. 2016
9.14
12 Trading Days
40.82%
Link
LONG
May 27. 2016
5.96
Jun 13. 2016
6.65
10 Trading Days
11.54%
Link
LONG
Aug 23. 2016
4.47
Sep 9. 2016
5.10
12 Trading Days
14.18%
Link
LONG
Nov 9. 2016
4.35
Nov 29. 2016
4.93
13 Trading Days
13.27%
Link
Company Information
Stock Symbol
ARGS
Exchange
NasdaqGM
Company URL
http://www.argostherapeutics.com
Company Phone
9192876300
CEO
Jeffrey D. Abbey
Headquarters
North Carolina
Business Address
4233 TECHNOLOGY DR, DURHAM, NC 27704
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001105533
About

Argos Therapeutics, Inc. focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America.

Description

Argos Therapeutics, Inc. focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.